Curated News
By: NewsRamp Editorial Staff
June 23, 2026

Quantum BioPharma Advances Novel MS Therapy Toward Phase 2 Trials

Discuss on Substack
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS, a first-in-class MS therapy targeting myelin protection, may offer a competitive edge over current immune-modulating treatments.
  • Lucid-MS aims to prevent and reverse myelin degradation with a non-immunomodulatory mechanism, validated by over a decade of research and Phase 1 safety data.
  • Lucid-MS could improve quality of life for MS patients by directly protecting myelin, potentially slowing or reversing disease progression.
  • Collaboration with Massachusetts General Hospital uses PET imaging to measure myelin integrity in MS patients, a novel diagnostic approach.

Impact - Why it Matters

This news matters because multiple sclerosis affects millions worldwide, and current treatments primarily manage symptoms or modulate the immune system without directly repairing myelin damage. Lucid-MS offers a potential breakthrough as a neuroprotective therapy that could prevent and reverse myelin degradation, addressing the root cause of disability progression. If successful in Phase 2 trials, it could transform MS treatment, providing patients with a therapy that directly protects nerve fibers. Additionally, the PET imaging collaboration could lead to better monitoring tools, improving clinical outcomes and quality of life for MS patients.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making strides in multiple sclerosis (MS) treatment with its novel drug candidate Lucid-MS, as highlighted in a recent BioMedWire editorial. Unlike conventional MS therapies that primarily target the immune system, Lucid-MS is a patented, first-in-class non-immunomodulatory neuroprotective therapy designed to directly protect the myelin sheath—the protective coating around nerve fibers that is damaged in MS. After successful Phase 1 safety and tolerability studies, Lucid-MS is preparing to enter Phase 2 clinical trials. Preclinical studies have demonstrated its ability to prevent and reverse myelin degradation, supported by over a decade of scientific research.

In addition to Lucid-MS, Quantum BioPharma is collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that could enable direct measurement of myelin integrity in MS patients. This advancement could significantly enhance the monitoring of disease progression and treatment efficacy. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., focuses on the development of Lucid-MS as a lead compound.

Quantum also retains a 19.84% stake in Unbuzzd Wellness Inc., which markets UNBUZZD(TM), an OTC product, and receives royalty payments up to $250 million, after which royalties drop to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses. For more details, view the full press release at https://ibn.fm/iZmx1.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma Advances Novel MS Therapy Toward Phase 2 Trials

blockchain registration record for this content.